




BioVendor

Research
and Diagnostic Products



HUMAN IFN γ ELISA

Product Data Sheet

Cat. No.: RBMS228R

For Research Use Only

CONTENTS

1	Intended Use	3
2	Summary	3
3	Principles of the Test	5
4	Reagents Provided	6
5	Storage Instructions – ELISA Kit	6
6	Specimen Collection and Storage Instructions	7
7	Materials Required But Not Provided	7
8	Precautions for Use	8
9	Preparation of Reagents	9
10	Test Protocol	12
11	Calculation of Results	14
12	Limitations	17
13	Performance Characteristics	17
14	References	21
15	Reagent Preparation Summary	22
16	Test Protocol Summary	23

➤➤ This kit is manufactured by:
BioVendor – Laboratorní medicína, a.s.

➤➤ Use only the current version of Product Data Sheet enclosed with the kit!

1 INTENDED USE

The human IFN γ ELISA is an enzyme-linked immunosorbent assay for the quantitative detection of human IFN γ . **The human IFN γ ELISA is for research use only. Not for diagnostic or therapeutic procedures.**

2 SUMMARY

IFN γ , also called Type II interferon, is a homodimeric glycoprotein containing approximately 21 to 24 kD subunits. The human IFN γ gene, situated on chromosome 12, contains three introns; the four exons code for a polypeptide of 166 amino acids, 20 of which constitute the signal peptide (11).

In contrast to IFN α and IFN β synthesis, which can occur in any cell, production of IFN γ is a function of T cells and NK cells. All IFN γ inducers activate T cells either in a polyclonal (mitogens or antibodies) or in a clonally restricted, antigen-specific, manner.

IFN γ is produced during infection by T cells of the cytotoxic/suppressor phenotype (CD8) and by a subtype of helper T cells, the Th1 cells. Th1 cells secrete IL-2, IL-3, TNF β and IFN γ , whereas Th2 cells mainly produce IL-3, IL-4, IL-5, and IL-10, but little or no IFN γ (9). IFN γ preferentially inhibits the proliferation of Th2 but not Th1 cells, indicating that the presence of IFN γ during an immune response will result in the preferential proliferation of Th1 cells (7).

Type II IFN or IFN γ is a lymphokine that displays no molecular homology with type I IFN, but shares some important biologic activities. Specifically, IFN γ induces an anti-viral state and is anti-proliferative. In addition, IFN γ has several properties related to immunoregulation.

(1) IFN γ is a potent activator of mononuclear phagocytes, e.g. IFN γ stimulates the expression of Mac-1, augments endocytosis and phagocytosis by monocytes (15), and activates macrophages to kill tumor cells by releasing reactive oxygen intermediates and TNF α (21).

(2) IFN γ induces or augments the expression of MHC antigens on macrophages, T and B cells and some tumor cell lines (3).

(3) On T and B cells IFN γ promotes differentiation. It enhances proliferation of activated B cells and can act synergistically with IL-2 to increase immunoglobulin light-chain synthesis. (8, 13). IFN γ is one of the natural B-cell differentiation factors (17).

(4) Finally, IFN γ activates neutrophils, NK cells and vascular endothelial cells (6).

The role of IFN γ as a disease marker has been demonstrated for a number of different pathological situations:

- infections: IFN γ is produced during viral infections (4).

IFN γ is a diagnostic tool for distinguishing tuberculous from other non-tuberculous ascites (5, 18). IFN γ values in pleural fluid are significantly higher in tuberculous pleuritis patients than those in non-tuberculous pleuritis patients, with a sensitivity and a specificity of 100% (1, 2). Therapy-induced (treatment with thalidomide) alleviation of clinical symptoms of erythema nodosum leprosum correlates with IFN γ and TNF α levels (14). Tuberculous leprosy patients

show increased lymphocyte proliferation and IFN γ production in response to stimulation with *Mycobacterium leprae* as compared to lepromatous leprosy patients and healthy individuals (16).

- autoimmune diseases: Accurate measurements of cellular production of cytokines, e.g. IFN γ is important in the design and monitoring of immunotherapy of multiple sclerosis (12).

- transplant rejection: Intragraft IFN γ mRNA expression occurs in active acute transplant rejection preceding clinical transplant rejection, thus offering an early diagnostic tool for detection of transplant rejection (10).

- allergy: IFN γ production by isolated lymphocytes is not detectable in patients with cow's milk allergy as compared to control individuals (19).


Infants who develop atopy produce significantly less IFN γ at birth compared to infants who do not develop atopy (20).

- diabetes: Peripheral blood lymphomononuclear cells from newly diagnosed type I diabetes produce significantly less IFN γ in comparison to controls and long-standing diabetes (4).

3 PRINCIPLES OF THE TEST

An anti-human IFN γ coating antibody is adsorbed onto microwells.


Coated Microwell



Human IFN γ present in the sample or standard binds to antibodies adsorbed to the microwells. A biotin-conjugated anti-human IFN γ antibody is added and binds to human IFN γ captured by the first antibody.

Figure 2


First Incubation



Following incubation unbound biotin-conjugated anti-human IFN γ antibody is removed during a wash step. Streptavidin-HRP is added and binds to the biotin-conjugated anti-human IFN γ antibody.

Figure 3


Second Incubation



Following incubation unbound Streptavidin-HRP is removed during a wash step, and substrate solution reactive with HRP is added to the wells.


Figure 4

Third Incubation



A coloured product is formed in proportion to the amount of human IFN γ present in the sample or standard. The reaction is terminated by addition of acid and absorbance is measured at 450 nm. A standard curve is prepared from 7 human IFN γ standard dilutions and human IFN γ sample concentration determined.

Figure 5



4 REAGENTS PROVIDED

- 1 aluminium pouch with a **Antibody Coated Microtiter Strips** with monoclonal antibody to human IFN γ
- 1 vial (100 μ l) **Biotin-Conjugate** anti-human IFN γ monoclonal antibody
- 1 vial (150 μ l) **Streptavidin-HRP**
- 2 vials human IFN γ **Standard** lyophilized, 200 ng/ml upon reconstitution
- 1 vial (12 ml) **Sample Diluent**

Please note: *In some, very rare cases, an insoluble precipitate of stabilizing protein has been seen in the Sample Diluent vial. This precipitate does not interfere in any way with the performance of the test and can thus be ignored.*

- 1 vial (5 ml) **Assay Buffer Concentrate 20x** (PBS with 1% Tween 20 and 10% BSA)
- 1 bottle (50 ml) **Wash Buffer Concentrate 20x** (PBS with 1% Tween 20)
- 1 vial (15 ml) **Substrate Solution** (tetramethyl-benzidine)
- 1 vial (12 ml) **Stop Solution** (1M Phosphoric acid)
- 1 vial (0.4 ml) **Blue-Dye**
- 1 vial (0.4 ml) **Green-Dye**
- 1 vial (0.4 ml) **Red-Dye**
- 4 **Adhesive Films**

5 STORAGE INSTRUCTIONS – ELISA KIT

Store kit reagents between 2° and 8°C. Immediately after use remaining reagents should be returned to cold storage (2° to 8°C). Expiry of the kit and reagents is stated on labels. Expiry of the kit components can only be guaranteed if the components are stored properly, and if, in case of repeated use of one component, this reagent is not contaminated by the first handling.

6 SPECIMEN COLLECTION AND STORAGE INSTRUCTIONS

Cell culture supernatant, serum and plasma (EDTA, citrate, heparinized) were tested with this assay. Other biological samples might be suitable for use in the assay. Remove serum or plasma from the clot or cells as soon as possible after clotting and separation.

Pay attention to a possible “**Hook Effect**” due to high sample concentrations (see chapter 11). Samples containing a visible precipitate must be clarified prior to use in the assay. Do not use grossly hemolyzed or lipemic specimens.

Samples should be aliquoted and must be stored frozen at -20°C to avoid loss of bioactive human IFN γ . If samples are to be run within 24 hours, they may be stored at 2° to 8°C (for sample stability refer to 13.5).

Avoid repeated freeze-thaw cycles. Prior to assay, the frozen sample should be brought to room temperature slowly and mixed gently.

7 MATERIALS REQUIRED BUT NOT PROVIDED

- 5 ml and 10 ml graduated pipettes
- 5 μ l to 1000 μ l adjustable single channel micropipettes with disposable tips
- 50 μ l to 300 μ l adjustable multichannel micropipette with disposable tips
- Multichannel micropipette reservoir
- Beakers, flasks, cylinders necessary for preparation of reagents
- Device for delivery of wash solution (multichannel wash bottle or automatic wash system)
- Microwell strip reader capable of reading at 450 nm (620 nm as optional reference wave length)
- Glass-distilled or deionized water
- Statistical calculator with program to perform regression analysis

8 PRECAUTIONS FOR USE

- All chemicals should be considered as potentially hazardous. We therefore recommend that this product is handled only by those persons who have been trained in laboratory techniques and that it is used in accordance with the principles of good laboratory practice. Wear suitable protective clothing such as laboratory overalls, safety glasses and gloves. Care should be taken to avoid contact with skin or eyes. In the case of contact with skin or eyes wash immediately with water. See material safety data sheet(s) and/or safety statement(s) for specific advice.
- Reagents are intended for in vitro diagnostic use only and are not for use in therapeutic procedures.
- Do not mix or substitute reagents with those from other lots or other sources.
- Do not use kit reagents beyond expiration date on label.
- Do not expose kit reagents to strong light during storage or incubation.
- Do not pipette by mouth.
- Do not eat or smoke in areas where kit reagents or samples are handled.
- Avoid contact of skin or mucous membranes with kit reagents or specimens.
- Rubber or disposable latex gloves should be worn while handling kit reagents or specimens.
- Avoid contact of substrate solution with oxidizing agents and metal.
- Avoid splashing or generation of aerosols.
- In order to avoid microbial contamination or cross-contamination of reagents or specimens which may invalidate the test use disposable pipette tips and/or pipettes.
- Use clean, dedicated reagent trays for dispensing the conjugate and substrate reagent.
- Exposure to acid inactivates the conjugate.
- Glass-distilled water or deionized water must be used for reagent preparation.
- Substrate solution must be at room temperature prior to use.
- Decontaminate and dispose specimens and all potentially contaminated materials as they could contain infectious agents. The preferred method of decontamination is autoclaving for a minimum of 1 hour at 121.5°C.
- Liquid wastes not containing acid and neutralized waste may be mixed with sodium hypochlorite in volumes such that the final mixture contains 1.0% sodium hypochlorite. Allow 30 minutes for effective decontamination. Liquid waste containing acid must be neutralized prior to the addition of sodium hypochlorite.

9 PREPARATION OF REAGENTS

Buffer concentrates should be brought to room temperature and should be diluted before starting the test procedure.

9.1 Wash Buffer

If crystals have formed in the **Wash Buffer Concentrate**, warm it gently until they have completely dissolved.

Pour entire contents (50 ml) of the Wash Buffer Concentrate into a clean 1000 ml graduated cylinder. Bring to final volume of 1000 ml with glass-distilled or deionized water. Mix gently to avoid foaming. The pH of the final solution should adjust to 7.4.

Transfer to a clean wash bottle and store at 2° to 25°C. Please note that Wash Buffer is stable for 30 days.

Wash Buffer may also be prepared as needed according to the following table:

Number of Strips	Wash Buffer Concentrate (ml)	Distilled Water (ml)
1 - 6	25	475
1 - 12	50	950

9.2 Assay Buffer (1x)

Pour the entire contents (5 ml) of the **Assay Buffer Concentrate** (20x) into a clean 100 ml graduated cylinder. Bring to final volume of 100 ml with distilled water. Mix gently to avoid foaming.

Store at 2° to 8°C. Please note that the Assay Buffer (1x) is stable for 30 days.

Assay Buffer (1x) may also be prepared as needed according to the following table:

Number of Strips	Assay Buffer Concentrate (ml)	Distilled Water (ml)
1 - 6	2.5	47.5
1 - 12	5.0	95.0

9.3 Biotin-Conjugate

Please note that the Biotin-Conjugate should be used within 30 minutes after dilution.

Make a 1:100 dilution of the concentrated **Biotin-Conjugate** solution with Assay Buffer (1x) in a clean plastic tube as needed according to the following table:

Number of Strips	Biotin-Conjugate (ml)	Assay Buffer (1x) (ml)
1 - 6	0.03	2.97
1 - 12	0.06	5.94

9.4 Streptavidin-HRP

Please note that the Streptavidin-HRP should be used within 30 minutes after dilution.

Make a 1:100 dilution of the concentrated Streptavidin-HRP solution with Assay Buffer (1x) in a clean plastic tube as needed according to the following table:

Number of Strips	Streptavidin-HRP (ml)	Assay Buffer (1x) (ml)
1 - 6	0.06	5.94
1 - 12	0.12	11.88

9.5 Human IFN γ Standard

Reconstitute **human IFN γ standard** by addition of distilled water.

Refer to the Quality Control Sheet for current volume of Distilled water needed for reconstitution of standard. Swirl or mix gently to insure complete and homogeneous solubilisation (concentration of reconstituted standard = 200 ng/ml).

The standard has to be used immediately after reconstitution and cannot be stored.

The concentrated **human IFN γ standard** must be diluted 1:1000 with Assay Buffer (1x) just prior to use in a clean plastic test tube according to the following dilution scheme:

Dilution 1: 100 μ l concentrated **human IFN γ standard** + 900 μ l Assay Buffer (1x) (concentration of dilution 1 = 20 ng/ml).

Dilution 2: 10 μ l dilution 1 + 990 μ l Assay Buffer (1x) (concentration of dilution 2 = 200 pg/ml).

Shake gently to mix.

Standard dilutions can be prepared directly on the microwell plate (see 10.c) or alternatively in tubes (see 9.5.1).

9.5.1 External Standard Dilution

Label 7 tubes, one for each standard point.

S1, S2, S3, S4, S5, S6, S7

Then prepare 1:2 serial dilutions for the standard curve as follows:


Pipette 225 μ l of Sample Diluent into each tube.

Pipette 225 μ l diluted standard (concentration = 200 pg/ml) into the first tube, labelled S1, and mix (concentration of standard 1 = 100 pg/ml). Pipette 225 μ l of this dilution into the second tube, labelled S2, and mix thoroughly before the next transfer.

Repeat serial dilutions 5 more times thus creating the points of the standard curve (see Figure 6).

Sample Diluent serves as blank.

Figure 6



9.6 Addition of Colour-giving Reagents: Blue-Dye, Green-Dye, Red-Dye

This procedure is optional, does not in any way interfere with the test results, and is designed to help the customer with the performance of the test, but can also be omitted, just following the instruction booklet.

Alternatively, the dye solutions from the stocks provided (*Blue-Dye*, *Green-Dye*, *Red-Dye*) can be added to the reagents according to the following guidelines:

1. Diluent: Before standard and sample dilution add the *Blue-Dye* at a dilution of 1:250 (see table below) to the appropriate diluent (1x) according to the test protocol. After addition of *Blue-Dye*, proceed according to the instruction booklet.

5 ml Sample Diluent	20 μ l <i>Blue-Dye</i>
12 ml Sample Diluent	48 μ l <i>Blue-Dye</i>
50 ml Sample Diluent	200 μ l <i>Blue-Dye</i>

2. Biotin-Conjugate: Before dilution of the concentrated Biotin-Conjugate, add the *Green-Dye* at a dilution of 1:100 (see table below) to the Assay Buffer (1x) used for the final conjugate dilution. Proceed after addition of *Green-Dye* according to the instruction booklet: Preparation of Biotin-Conjugate.

3 ml Assay Buffer (1x)	30 μ l <i>Green-Dye</i>
6 ml Assay Buffer (1x)	60 μ l <i>Green-Dye</i>


3. Streptavidin-HRP: Before dilution of the concentrated Streptavidin-HRP, add the *Red-Dye* at a dilution of 1:250 (see table below) to the Assay Buffer (1x) used for the final Streptavidin-HRP dilution. Proceed after addition of *Red-Dye* according to the instruction booklet: Preparation of Streptavidin-HRP

6 ml Assay Buffer (1x)	24 μ l <i>Red-Dye</i>
12 ml Assay Buffer (1x)	48 μ l <i>Red-Dye</i>

10 TEST PROTOCOL

- Determine the number of microwell strips required to test the desired number of samples plus appropriate number of wells needed for running blanks and standards. Each sample, standard, blank and optional control sample should be assayed in duplicate. Remove extra microwell strips from holder and store in foil bag with the desiccant provided at 2°-8°C sealed tightly.
- Wash the microwell strips twice with approximately 400 µl **Wash Buffer** per well with thorough aspiration of microwell contents between washes. Allow the Wash Buffer to sit in the wells for about **10 – 15 seconds** before aspiration. Take care not to scratch the surface of the microwells. After the last wash step, empty wells and tap microwell strips on absorbent pad or paper towel to remove excess Wash Buffer. Use the microwell strips immediately after washing. Alternatively microwell strips can be placed upside down on a wet absorbent paper for not longer than 15 minutes. **Do not allow wells to dry.**
- Standard dilution on the microwell plate** (Alternatively the standard dilution can be prepared in tubes - see 9.5.1): Add 100 µl of Sample Diluent in duplicate to all **standard wells**. Pipette 100 µl of prepared **standard** (see Preparation of Standard 0, concentration = 200 pg/ml) in duplicate into well A1 and A2 (see Table 1). Mix the contents of wells A1 and A2 by repeated aspiration and ejection (concentration of standard 1, S1 = 100 pg/ml), and transfer 100 µl to wells B1 and B2, respectively (see Figure 7). Take care not to scratch the inner surface of the microwells. Continue this procedure 5 times, creating two rows of human IFN γ standard dilutions ranging from 100.00 to 1.56 pg/ml. Discard 100 µl of the contents from the last microwells (G1, G2) used.

Figure 7



In case of an **external standard dilution** (see 9.5.1), pipette 100 µl of these standard dilutions (S1 - S7) in the standard wells according to Table 1.

Table 1

Table depicting an example of the arrangement of blanks, standards and samples in the microwell strips:

	1	2	3	4
A	Standard 1 (100.00 pg/ml)	Standard 1 (100.00 pg/ml)	Sample 1	Sample 1
B	Standard 2 (50.00 pg/ml)	Standard 2 (50.00 pg/ml)	Sample 2	Sample 2
C	Standard 3 (25.00 pg/ml)	Standard 3 (25.00 pg/ml)	Sample 3	Sample 3
D	Standard 4 (12.50 pg/ml)	Standard 4 (12.50 pg/ml)	Sample 4	Sample 4
E	Standard 5 (6.25 pg/ml)	Standard 5 (6.25 pg/ml)	Sample 5	Sample 5
F	Standard 6 (3.13 pg/ml)	Standard 6 (3.13 pg/ml)	Sample 6	Sample 6
G	Standard 7 (1.56 pg/ml)	Standard 7 (1.56 pg/ml)	Sample 7	Sample 7
H	Blank	Blank	Sample 8	Sample 8

- d. Add 100 µl of **Sample Diluent** in duplicate to the **blank wells**.
- e. Add 50 µl of **Sample Diluent** to the **sample wells**.
- f. Add 50 µl of each **sample** in duplicate to the **sample wells**.
- g. Prepare **Biotin-Conjugate** (see Preparation of Biotin-Conjugate 9.3).
- h. Add 50 µl of **Biotin-Conjugate** to all wells.
- i. Cover with an adhesive film and incubate at room temperature (18 to 25°C) for 2 hours, if available on a microplate shaker set at 100 rpm.
- j. Prepare **Streptavidin-HRP** (refer to Preparation of Streptavidin-HRP 9.4).
- k. Remove adhesive film and empty wells. **Wash** microwell strips 3 times according to point b. of the test protocol. Proceed immediately to the next step.
- l. Add 100 µl of diluted **Streptavidin-HRP** to all wells, including the blank wells.
- m. Cover with an adhesive film and incubate at room temperature (18° to 25°C) for 1 hour, if available on a microplate shaker set at 100 rpm.
- n. Remove adhesive film and empty wells. **Wash** microwell strips 3 times according to point b. of the test protocol. Proceed immediately to the next step.
- o. Pipette 100 µl of **TMB Substrate Solution** to all wells.
- p. Incubate the microwell strips at room temperature (18° to 25°C) for about 10 min. Avoid direct exposure to intense light. **The colour development on the plate should be monitored and the substrate reaction stopped (see next point of this protocol) before positive wells are no longer properly recordable. Determination of the ideal time period for colour development has to be done individually for each assay.** It is recommended to add the stop solution when the highest standard has developed a dark blue colour. Alternatively the colour development can be monitored by the ELISA reader at

620 nm. The substrate reaction should be stopped as soon as Standard 1 has reached an OD of 0.6 – 0.65.

- q. Stop the enzyme reaction by quickly pipetting 100 µl of **Stop Solution** into each well. It is important that the Stop Solution is spread quickly and uniformly throughout the microwells to completely inactivate the enzyme. Results must be read immediately after the Stop Solution is added or within one hour if the microwell strips are stored at 2 - 8°C in the dark.
- r. Read absorbance of each microwell on a spectro-photometer using 450 nm as the primary wave length (optionally 620 nm as the reference wave length; 610 nm to 650 nm is acceptable). Blank the plate reader according to the manufacturer's instructions by using the blank wells. Determine the absorbance of both the samples and the standards.

Note: In case of incubation without shaking the obtained O.D. values may be lower than indicated below. Nevertheless the results are still valid.

11 CALCULATION OF RESULTS

- Calculate the average absorbance values for each set of duplicate standards and samples. Duplicates should be within 20 per cent of the mean value.
- Create a standard curve by plotting the mean absorbance for each standard concentration on the ordinate against the human IFN γ concentration on the abscissa. Draw a best fit curve through the points of the graph (a 5-parameter curve fit is recommended).
- To determine the concentration of circulating human IFN γ for each sample, first find the mean absorbance value on the ordinate and extend a horizontal line to the standard curve. At the point of intersection, extend a vertical line to the abscissa and read the corresponding human IFN γ concentration.
- **If instructions in this protocol have been followed samples have been diluted 1:2 (50 µl sample + 50 µl Sample Diluent), the concentration read from the standard curve must be multiplied by the dilution factor (x 2).**
- **Calculation of samples with a concentration exceeding standard 1 may result in incorrect, low human IFN γ levels (Hook Effect). Such samples require further external predilution according to expected human IFN γ values with Sample Diluent in order to precisely quantitate the actual human IFN γ level.**
- It is suggested that each testing facility establishes a control sample of known human IFN γ concentration and runs this additional control with each assay. If the values obtained are not within the expected range of the control, the assay results may be invalid.
- A representative standard curve is shown in Figure 8. This curve cannot be used to derive test results. Each laboratory must prepare a standard curve for each group of microwell strips assayed.

Figure 8

Representative standard curve for human IFN γ ELISA. Human IFN γ was diluted in serial 2-fold steps in Sample Diluent. Do not use this standard curve to derive test results. A standard curve must be run for each group of microwell strips assayed.




Table 2

Typical data using the human IFN γ ELISA

Measuring wavelength: 450 nm

Reference wavelength: 620 nm

Standard	Human IFN γ Concentration (pg/ml)	O.D. at 450 nm	Mean O.D. at 450 nm	C.V. (%)
1	100.00	2.210	2.177	2.2
	100.00	2.143		
2	50.00	1.307	1.342	3.6
	50.00	1.376		
3	25.00	0.802	0.804	0.3
	25.00	0.805		
4	12.50	0.450	0.463	3.8
	12.50	0.475		
5	6.25	0.257	0.254	2.0
	6.25	0.250		
6	3.13	0.139	0.136	3.7
	3.13	0.132		
7	1.56	0.085	0.081	7.0
	1.56	0.077		
Blank	0	0.027	0.027	
	0	0.027		

The OD values of the standard curve may vary according to the conditions of assay performance (e.g. operator, pipetting technique, washing technique or temperature effects). Furthermore shelf life of the kit may affect enzymatic activity and thus colour intensity. Values measured are still valid.

12 LIMITATIONS

- Since exact conditions may vary from assay to assay, a standard curve must be established for every run.
- Bacterial or fungal contamination of either screen samples or reagents or cross-contamination between reagents may cause erroneous results.
- Disposable pipette tips, flasks or glassware are preferred, reusable glassware must be washed and thoroughly rinsed of all detergents before use.
- Improper or insufficient washing at any stage of the procedure will result in either false positive or false negative results. Empty wells completely before dispensing fresh wash solution, fill with Wash Buffer as indicated for each wash cycle and do not allow wells to sit uncovered or dry for extended periods.
- The use of radioimmunotherapy has significantly increased the number of patients with human anti-mouse IgG antibodies (HAMA). HAMA may interfere with assays utilizing murine monoclonal antibodies leading to both false positive and false negative results. Serum samples containing antibodies to murine immunoglobulins can still be analysed in such assays when murine immunoglobulins (serum, ascitic fluid, or monoclonal antibodies of irrelevant specificity) are added to the sample.

13 PERFORMANCE CHARACTERISTICS

13.1 Sensitivity

The limit of detection of human IFN γ defined as the analyte concentration resulting in an absorbance significantly higher than that of the dilution medium (mean plus 2 standard deviations) was determined to be 0.99 pg/ml (mean of 6 independent assays).

13.2 Reproducibility

13.2.1 Intra-assay

Reproducibility within the assay was evaluated in 3 independent experiments. Each assay was carried out with 6 replicates of 8 serum samples containing different concentrations of human IFN γ . 2 standard curves were run on each plate. Data below show the mean human IFN γ concentration and the coefficient of variation for each sample (see Table 3). The calculated overall intra-assay coefficient of variation was 4.5%.

Table 3

The mean human IFN γ concentration and the coefficient of variation for each sample

Sample	Experiment	Mean Human IFN γ Concentration (pg/ml)	Coefficient of Variation (%)
1	1	173	2.5
	2	184	7.3
	3	160	2.1
2	1	216	3.0
	2	220	5.4
	3	212	1.7
3	1	101	2.0
	2	112	2.4
	3	100	0.3
4	1	290	1.6
	2	300	3.7
	3	277	0.5
5	1	18.0	4.9
	2	18.5	7.8
	3	18.7	6.7
6	1	27.9	3.1
	2	31.1	8.0
	3	27.4	6.7
7	1	75.4	7.7
	2	69.5	5.3
	3	61.4	4.6
8	1	9.6	2.9
	2	11.0	7.2
	3	9.7	10.7

13.2.2 Inter-assay

Assay to assay reproducibility within one laboratory was evaluated in 3 independent experiments. Each assay was carried out with 6 replicates of 8 serum samples containing different concentrations of human IFN γ . 2 standard curves were run on each plate. Data below show the mean human IFN γ concentration and the coefficient of variation calculated on 18 determinations of each sample (see Table 4). The calculated overall inter-assay coefficient of variation was 5.7%.

Table 4

The mean human IFN γ concentration and the coefficient of variation of each sample

Sample	Mean Human IFN γ Concentration (pg/ml)	Coefficient of Variation (%)
1	172.0	7.2
2	216.0	1.8
3	104.0	5.9
4	289.0	3.9
5	18.4	2.0
6	28.8	6.8
7	68.8	10.3
8	10.1	7.8

13.3 Spiking Recovery

The spiking recovery was evaluated by spiking 4 levels of human IFN γ into a pooled normal serum sample. Recoveries were determined in 3 independent experiments with 8 replicates each. The unspiked serum was used as blank in these experiments.

The recovery ranged from 88% to 112% with an overall mean recovery of 97%.

13.4 Dilution Linearity

4 serum samples with different levels of human IFN γ were analysed at serial 2 fold dilutions with 4 replicates each. The recovery ranged from 86% to 114% with an overall recovery of 99% (see Table 5).

Table 5

Sample	Dilution	Expected Human IFN γ Concentration (pg/ml)	Observed Human IFN γ Concentration (pg/ml)	Recovery of Expected Human IFN γ Concentration (%)
1	1:2	--	144.4	--
	1:4	72.2	67.0	93
	1:8	36.1	35.6	99
	1:16	18.0	15.8	87
2	1:2	--	161.7	--
	1:4	80.8	81.2	101
	1:8	40.4	44.1	109
	1:16	20.2	23.0	114
3	1:2	--	100.4	--
	1:4	50.2	44.9	90
	1:8	25.1	23.2	93
	1:16	12.5	10.7	86
4	1:2	--	261.5	--
	1:4	130.8	140.5	108
	1:8	65.4	69.4	106
	1:16	32.7	32.5	99

13.5 Sample Stability

13.5.1 Freeze-Thaw Stability

Aliquots of serum and cell culture supernatant samples (spiked or unspiked) were stored at -20°C and thawed 5 times, and the human IFN γ levels determined. A significant decrease of human IFN γ immunoreactivity (30%) was detected for 2 or more cycles of freezing and thawing. Therefore samples should be stored in aliquots at -20°C and thawed only once.

13.5.2 Storage Stability

Aliquots of serum and cell culture supernatant samples (spiked or unspiked) were stored at -20°C, 2-8°C, room temperature (RT) and at 37°C, and the human IFN γ level determined after 24 h. There was no significant loss of human IFN γ immunoreactivity detected during storage at -20°C, 2-8°C and RT. A significant loss of human IFN γ immunoreactivity (50%) was detected during storage at 37°C after 24 h.

13.6 Comparison of Serum and Plasma

From two individuals, serum as well as EDTA, citrate, and heparin plasma obtained at the same time point were evaluated. Human IFN γ concentrations were not significantly different and therefore all these body fluids are suitable for the assay. It is nevertheless highly recommended to assure the uniformity of blood preparations.

13.7 Specificity

The interference of circulating factors of the immune system was evaluated by spiking these proteins at physiologically relevant concentrations into a human IFN γ positive serum. There was no crossreactivity detected.

13.8 Expected Values

A panel of 22 sera samples from randomly selected apparently healthy donors (males and females) was tested for human IFN γ .

The detected human IFN γ levels ranged between less than 1.5 and 168.0 pg/ml with a mean level of 10.4 pg/ml and a standard deviation of 35.0 pg/ml (13 samples less than 1.5 pg/ml).

13.9 Calibration

The immunoassay is calibrated with highly purified recombinant human IFN γ which has been evaluated against the international Reference Standard NIBSC 82/587 and has been shown to be equivalent.

NIBSC 82/587 is quantitated in International Units (IU), 1IU corresponding to 50 pg human IFN γ .

14 REFERENCES

- 1) Aoki, Y., Katoh, O., Nakanishi, Y., Kuroki, S., and Yamada, H. (1994). A comparison study of IFN-gamma, ADA, and CA125 as the diagnostic parameters in tuberculous pleuritis. *Respir. Med.* 88, 139-143.
- 2) Capobianchi, M. R., Ameglio, F., Tosi, R., and Dolei, A. (1985). Differences in the expression and release of DR, BR, and DQ molecules in human cells treated with recombinant interferon gamma: comparison to other interferons. *Hum. Immunol.* 13, 1-11.
- 3) Ciampolillo, A., Guastamacchia, E., Caragiulo, L., Lollino, G., De Robertis, O., Lattanzi, V., and Giorgino, R. (1993). In vitro secretion of interleukin-1 beta and interferon-gamma by peripheral blood lymphomononuclear cells in diabetic patients. *Diabetes Res.*
- 4) Cunningham, A. L., Nelson, P. A., Fathman, C. G., and Merigan, T. C. (1985). Interferon gamma production by herpes simplex virus antigen-specific T cell clones from patients with recurrent herpes labialis. *J. Gen. Virol.* 66, 249-258.
- 5) Davidson, P. M., Creati, L., Wood, P. R., Robertson, D. M., and Hosking, C. S. (1993). Lymphocyte production of gamma-interferon as a test for non-tuberculous mycobacterial lymphadenitis in childhood. *Eur. J. Pediatr.* 152, 31-35.
- 6) Edwards, B. S., Merritt, J. A., Fuhlbrigge, R. C., and Borden, E. C. (1985). Low doses of interferon alpha result in more effective clinical natural killer cell activation. *J. Clin. Invest.*
- 7) Gajewski, T. F., and Fitch, F. W. (1993). Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. *J. Immunol.* 140, 4245-4252.
- 8) Le thi Bich Thuy, Queen, C., and Fauci, A. S. (1986). Interferon-gamma induces light chain synthesis in interleukin 2 stimulated human B cells. *Eur. J. Immunol.* 16, 547-550.
- 9) Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A., and Coffman, R. L. (1986). Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. *J. Immunol.* 136, 2348-2357.
- 10) Nast, C. C., Zuo, X. J., Prehn, J., Danovitch, G. M., Wilkinson, A., and Jordan, S. C. (1994). Gamma-interferon gene expression in human renal allograft fine-needle aspirates. *Transplantation* 57,498-502.
- 11) Naylor, S. L., Sakaguchi, A. Y., Shows, T. B., Law, M. L., Goeddel, D. V., and Gray, P. W. (1983). Human immune interferon gene is located on chromosome 12. *J. Exp. Med.*
- 12) Olsson, T. Multiple sclerosis, cerebrospinal fluid. (1994). *Ann. Neurol.* 36 Suppl, 100-102.
- 13) Romagnani, S., Giudizi, M. G., Biagiotti, R., Almerigogna, F., Mingari, C., Maggi, E., Liang, C. M., and Moretta, L. (1986). B cell growth factor activity of interferon-gamma. Recombinant human interferon-gamma promotes proliferation of anti-mu-activated human B lymphocytes. *J. Immunol.* 136, 3513-3516.
- 14) Sampaio, E. P., Kaplan, G., Miranda, A., Nery, J. A., Miguel, C. P., Viana, S. M., and Sarno, E. N. (1993). The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. *J. Infect. Dis.* 168, 408-414.

- 15) Sastre, L., Roman, J. M., Teplow, D. B., Dreyer, W. J., Gee, C. E., Larson, R. S., Roberts, T. M., and Springer, T. A. (1986). A partial genomic DNA clone for the alpha subunit of the mouse complement receptor type 3 and cellular adhesion molecule Mac-1. *Proc. Natl. Acad. Sci. U. S. A.* 83, 5644-5648.
- 16) Shinde, S. R., Chiplunkar, S. V., Butlin, R., Samson, P. D., Deo, M. G., and Gangal, S. G. (1993). Lymphocyte proliferation, IFN-gamma production and limiting dilution analysis of T-cell responses to ICRC and Mycobacterium leprae antigens in leprosy patients. *Int. J. Lepr. Other Mycobact. Dis.* 61, 51-58.
- 17) Sidman, C. L., Marshall, J. D., Shultz, L. D., Gray, P. W., and Johnson, H. M. (1984). Gamma-interferon is one of several direct B cell-maturing lymphokines. *Nature* 309,
- 18) Soliman, A. A., el Aggan, H. A., el Hefnawy, A. M., Mahmoud, S. A., and Abo Deya, S. H. (1994). The value of ascites adenosine deaminase activity and interferon gamma level in discriminating tuberculous from non-tuberculous ascites. *J. Egypt. Soc. Parasitol.* 24,
- 19) Suomalainen, H., Soppi, E., Laine, S., and Isolauri, E. (1993). Immunologic disturbances in cow's milk allergy, 2: Evidence for defective interferon-gamma generation. *Pediatr. Allergy Immunol.* 4, 203-207.

15 REAGENT PREPARATION SUMMARY

15.1 Wash Buffer

Add **Wash Buffer Concentrate** 20x (50 ml) to 950 ml distilled water.

Number of Strips	Wash Buffer Concentrate (ml)	Distilled Water (ml)
1 - 6	25	475
1 - 12	50	950

15.2 Assay Buffer (1x)

Add **Assay Buffer Concentrate** 20x (5 ml) to 95 ml distilled water.

Number of Strips	Assay Buffer Concentrate (ml)	Distilled Water (ml)
1 - 6	2.5	47.5
1 - 12	5.0	95.0

15.3 Biotin-Conjugate

Make a 1:100 dilution of **Biotin-Conjugate** in Assay Buffer (1x):

Number of Strips	Biotin-Conjugate (ml)	Assay Buffer (1x) (ml)
1 - 6	0.03	2.97
1 - 12	0.06	5.94

15.4 Streptavidin-HRP

Make a 1:100 dilution of **Streptavidin-HRP** in Assay Buffer (1x):

Number of Strips	Streptavidin-HRP (ml)	Assay Buffer (1x) (ml)
1 - 6	0.06	5.94
1 - 12	0.12	11.88


15.5 Human IFN γ Standard

Reconstitute lyophilized **human IFN γ standard** with distilled water. (Reconstitution volume is stated in the Quality Control Sheet). The concentrated **human IFN γ standard** must be diluted 1:1000 with Assay Buffer (1x).

16 TEST PROTOCOL SUMMARY

1. Determine the number of microwell strips required.
2. Wash microwell strips twice with Wash Buffer.
3. Standard dilution on the microwell plate: Add 100 μ l Sample Diluent, in duplicate, to all standard wells. Pipette 100 μ l prepared standard into the first wells and create standard dilutions by transferring 100 μ l from well to well. Discard 100 μ l from the last wells. Alternatively external standard dilution in tubes (see 9.5.1): Pipette 100 μ l of these standard dilutions in the microwell strips.
4. Add 100 μ l Sample Diluent, in duplicate, to the blank wells.
5. Add 50 μ l Sample Diluent to sample wells.
6. Add 50 μ l sample in duplicate, to designated sample wells.
7. Prepare Biotin-Conjugate.
8. Add 50 μ l Biotin-Conjugate to all wells.
9. Cover microwell strips and incubate 2 hours at room temperature (18° to 25°C).
10. Prepare Streptavidin-HRP.
11. Empty and wash microwell strips 3 times with Wash Buffer.
12. Add 100 μ l diluted Streptavidin-HRP to all wells.
13. Cover microwell strips and incubate 1 hour at room temperature (18° to 25°C).
14. Empty and wash microwell strips 3 times with Wash Buffer.
15. Add 100 μ l of TMB Substrate Solution to all wells.
16. Incubate the microwell strips for about 10 minutes at room temperature (18° to 25°C).
17. Add 100 μ l Stop Solution to all wells.
18. Blank microwell reader and measure colour intensity at 450 nm.

Note: If instructions in this protocol have been followed samples have been diluted 1:2 (50 μ l sample + 50 μ l Sample Diluent), the concentration read from the standard curve must be multiplied by the dilution factor (x 2).



HEADQUARTERS: BioVendor Laboratorní medicina, a.s.	CTPark Modrice Evropska 873	664 42 Modrice CZECH REPUBLIC	Phone: +420-549-124-185 Fax: +420-549-211-460	E-mail: info@biovendor.com Web: www.biovendor.com
EUROPEAN UNION: BioVendor GmbH	Im Neuenheimer Feld 583	D-69120 Heidelberg GERMANY	Phone: +49-6221-433-9100 Fax: +49-6221-433-9111	E-mail: infoEU@biovendor.com
USA, CANADA AND MEXICO: BioVendor LLC	1463 Sand Hill Road Suite 227	Candler, NC 28715 USA	Phone: +1-828-670-7807 +1-800-404-7807 Fax: +1-828-670-7809	E-mail: infoUSA@biovendor.com
CHINA - Hong Kong Office: BioVendor Laboratories Ltd	Room 4008 Hong Kong Plaza, No.188	Connaught Road West Hong Kong, CHINA	Phone: +852-2803-0523 Fax: +852-2803-0525	E-mail: infoHK@biovendor.com
CHINA – Mainland Office: BioVendor Laboratories Ltd	Room 2405 YiYa Tower TianYu Garden, No.150	Lihe Zhong Road Guang Zhou, CHINA	Phone: +86-20-8706-3029 Fax: +86-20-8706-3016	E-mail: infoCN@biovendor.com